806 results about "In vivo experiment" patented technology

The present invention relates to the synthesis of beta-tetrahydro carboline carboxylic acid and its nanoparticle preparation; liquid phase process of gradually grafting peptide to obtain protected tetrapeptide intermediate, which, after eliminating its Boc, is condensated with N-Boc-beta-tetrahydro carboline carboxylic acid and further HF treated to eliminate its protection to obtain the said compound; the nanoparticle of tetrahydro carboline carboxylic acid and the in-vitro and in-vivo activity of said compound in-vitro and in-vivo experiments show that the compound of the present invention has excellent activity of resisting blood platelet aggregation, effect of resisting cell adhesion and effect of resisting thrombus.

The invention provides a BCMA-based (B cell maturation antigen-based) chimeric antigen receptor, comprising following cis-form cascade domains: CD8a leader region, scFv fragment BCMA scFv of anti-BCMA antibody, CD8a hinge region and transmembrane region, CD28 intracellular signal domain and CD3 Zeta intracellular signal domain; the CD3 Zeta intracellular signal domain is wild CD3 Zetaintracellular signal domain or mutant CD3 Zeta mut intracellular signal domain; the BCMA-based chimeric antigen receptor can enhance anti-apoptotic capability of T-cells and enhance CAR T-cell and antigen bonding and signal conduction; T-cells with the BCMA-based chimeric antigen receptor show good tumor targeting performance in in-vivo experiments, tumors diminish significantly after two weeks of dosage, and the T-cells have excellent therapeutic effect in vivo.

The invention provides application of piperlongumine derivatives to the preparation of a medicament for treating a cancer and a medicinal composition which uses the piperlongumine derivatives as active ingredients and can be used for treating the cancer. The invention provides various piperlongumine derivatives which are extracted from natural plants and are synthetized artificially. Experiments prove that the compounds can be used for selectively killing cancer cells without influencing the physiological functions of normal cells, and animal in-vivo experiments prove that the compounds can be used for obviously inhibiting tumor growth without influencing the normal physiological functions of animals so as to show that the compounds can be used for preparing the novel anti-cancer medicament capable of selectively killing the cancer cells.

The invention discloses the use of piperlongumine derivatives in the preparation of medicines for treating cancers and anticancer medicinal compositions taking the piperlongumine derivatives as active ingredients. The invention provides several piperlongumine derivatives, which are extracted from natural plants and synthesized artificially. Experiments prove that these compounds can selectively kill cancer cells without influencing the physiological functions of normal cells. Animal in-vivo experiments prove that these compounds can obviously suppress the growth of tumors without influencing the normal physiological functions of animals. Thus, these compounds can be used for preparing new anticancer medicines capable of killing cancer cells selectively.

The invention discloses a coreopsis tinctoria nutt extract and application of the coreopsis tinctoria nutt extract in preparation of medicines for treating hyperlipemia and anti-oxidation medicines. A method for preparing the coreopsis tinctoria nutt extract comprises the following steps: performing reflux extraction on a coreopsis tinctoria nutt medicinal material for 2-3 times by 12-25 times of 30-75% ethanol the amount of which is 12-25 times of the amount of the coreopsis tinctoria nutt medicinal material; mixing extract liquids, and concentrating to obtain extracting concentrate; diluting the extracting concentrate by water; refining by an AB-8 macroporous resin; sequentially eluting by water, 10% ethanol, 50-75% ethanol and 95% ethanol, and collecting the part eluted by 50-75% ethanol; concentrating and drying. The coreopsis tinctoria nutt extract comprises 10 flavones serving as main components, wherein the total content of marein and flavanomarein is more than 10 percent. Animal in-vivo experiments indicate that the coreopsis tinctoria nutt extract has a certain blood-fat regulating effect; and in-vitro anti-free radical scavenging experiments indicate that the coreopsis tinctoria nutt extract has a certain anti-oxidation effect, and flavanomarein, marein and the like are main anti-oxidation components.

Contrast agents incorporating super-paramagnetic iron-oxide (SPIO) nanoparticles have shown promise as a means to visualize labeled cells using MRI. Labeled cells cause significant signal dephasing due to the magnetic field inhomogeneity induced in water molecules near the cell. With the resulting signal void as the means for detection, the particles are behaving as a negative contrast agent, which can suffer from partial-volume effects. Disclosed is a new method for imaging labeled cells with positive contrast. Spectrally-selective RF pulses are used to excite and refocus the off-resonance water surrounding the labeled cells so that only the fluid and tissue immediately adjacent to the labeled cells are visible in the image. Phantom, in vitro, and in vivo experiments show the feasibility of the new method. A significant linear correlation (r=0.87, p<0.005) between the estimated number of cells and the signal has been observed.

The invention relates to a ursolic acid-aspirin conjugate shown in a formula (I) and application thereof in preparing drugs for preventing tumor metastasis. In vivo experiments verify that the ursolic acid-aspirin conjugate provided by the invention has a remarkable inhibitory effect on adhesion, migration, invasion and the like of tumor cells. in vivo animal experiments verify that the ursolic acid-aspirin conjugate can be used for reducing experimental pulmonary metastasis of 4T1 breast cancer of a rat and showing a relatively good tumor metastasis resisting effect. The ursolic acid-aspirin conjugate provided by the invention can be applied to preventive drugs for tumor metastasis, thereby providing novel selection for developing new drugs for tumor metastasis and preventing postoperative retransfer of malignant tumors. The formula (I) is shown in the description.

The invention relates to a method for measuring the acoustic impedance of an organism based on ultrasound steady state reflected waves, which comprises that (1) multiple frequency continuous baseband signals which are mutually orthometric are structured by using orthogonal frequency division multiplexing modulation mode; (2) an ultrasonic probe sends out the multiple frequency continuous baseband signals; (3) an ultrasound transducer detects reflected state echo signals; and finally the amplitude of reflected waves of a no uniform reflecting interface and phase difference opposite to incident waves are found out by solving equations set. A device realizing the method comprises an ultrasonic probe, a control unit, a transceiving unit, a processing unit and a display element which are respectively connected with the control unit. The ultrasonic probe is connected with the transceiving unit. The processing unit is respectively connected with the transceiving unit and the display element. The method has high calculation accuracy, good anti-interference, good anti-noise capability. Only one probe is needed, thus causing that the cost of development devices is reduced. And the measuring method is simple and can be used in vivo experiment.

The invention relates to an extract of persimmon leaves which are rich in flavones and a process for preparation, and the usage for preparing medicaments and / or health products for preventing and / or curing glucose and lipid metabolism and the relative illness, wherein glucose and lipid metabolism and the relative illness comprise hyperglycemia, diabetes mellitus and metabolism syndrome. Pharmacological researches, animal in vivo experiments and clinical researches show that the extracts of persimmon leaves which are rich in flavones have obvious functions of decompression, antihyperglycemic and antihypelipidemic, clinical curative effects for curing metabolism syndrome of diabetes, hyperlipemia, and hypertension are precise, and a toxicity test shows that the toxicity of the extracts of persimmon leaves which are rich in flavones of the invention is lower, and the security is high.

The invention belongs to the field of pharmaceutical chemistry, and specifically relates to an application of specific chalcone compounds in the preparations of inflammation resisting medicines and medicines used for treating inflammation-related diseases. With the chalcone compounds, expression and release of various inflammatory factors such as TNF-alpha, IL-6, COX-2, IL-1beta and IL-12 can be inhibited; nuclear translocation of an inflammation-regulation-related nuclear factor -kappaB can be substantially inhibited; and phosphorylation of inflammation signal pathways ERK and p38 can be inhibited. As a result of in-vivo experiments, with the compounds, the survival rate of LPS-introduced mice mortality can be substantially improved.

The present invention discloses the application of bakuchiol compound in preparing medicine for treating psychogenic diseases and neurogenic diseases. Extracorporeal experiment and animal experiment show that the bakuchiol compound can suppressing dopamine transport protein, noradrenalin transport protein and 5-hydroxy tryptamine transport protein selectively, and no influence on gamma-aminobutyric acid transport protein and L-glytamic acid transport protein, no cytotoxicity, and antidepressant effect higher than available antidepressant medicine amfebutamoe hydrochloride. Therefore, the bakuchiol compound has excellent marketability in preparing medicine for treating psychogenic diseases and neurogenic diseases.

Contrast agents incorporating super-paramagnetic iron-oxide (SPIO) nanoparticles have shown promise as a means to visualize labeled cells using MRI. Labeled cells cause significant signal dephasing due to the magnetic field inhomogeneity induced in water molecules near the cell. With the resulting signal void as the means for detection, the particles are behaving as a negative contrast agent, which can suffer from partial-volume effects. Disclosed is a new method for imaging labeled cells with positive contrast. Spectrally-selective RF pulses are used to excite and refocus the off-resonance water surrounding the labeled cells so that only the fluid and tissue immediately adjacent to the labeled cells are visible in the image. Phantom, in vitro, and in vivo experiments show the feasibility of the new method. A significant linear correlation (r=0.87, p<0.005) between the estimated number of cells and the signal has been observed.

The invention discloses an application of in-situ crosslinking hydrogel in preparing artificial vitreous bodies, which is characterized in that the in-situ crosslinking hydrogel is prepared by in-situ crosslinking after mixing a four-arm-end mercapto polyethylene glycol solution shown in the formula (I) and a polymer solution shown in the formula (II); wherein m in the formula (I) is an integer larger than 1, and n in the formula (II) is an integer larger than 1; and the two solutions are filled in eyes without vitreous bodies after mixing and can effectively form gel. A cell experiment and an animal in vivo experiment prove that the in-situ crosslinking hydrogel does not cause obvious inflammatory reaction and intraocular organ toxic reaction and can be used as the artificial vitreous bodies.

The invention, which belongs to the field of biochemistry, relates to a tumor-targeting functionalized quantum dot and a preparation method thereof. The functionalized quantum dot consists of folic acid, cyclodextrin and quantum dot, and part of folic acid molecules are contained in the hydrophobic cavity of the cyclodextrin to form folic acid-cyclodextrin inclusion compound, which is then combined with the surface of the quantum dot. In the process of preparing the functionalized quantum dot, the folic acid is first combined with the Gamma-cyclodextrin to form the inclusion compound, and the Gamma-cyclodextrin-folic acid inclusion compound is then modified on the surface of the quantum dot, so that the dual-function nano material with excellent fluorescent characteristic and tumor-targeting property is produced. Since the Gamma-cyclodextrin is used to include the folic acid, the water-solubility and dispersibility of the folic acid are improved. The folic acid and the quantum dot are connected together by an effective method, and the produced fluorescent probe can be used for biological research on tumor cells. The preparation method is simple, the cost is low, and the screening of a variety of tumor cells and an in-vivo experiment on mice indicate that the material is characterized by low toxicity, high selectivity and the like.

The invention belongs to the field of pharmacy, and relates to aminomethylpiperidine derivatives as shown in a general formula (I) or salts thereof, and a preparation method for the aminomethylpiperidine derivatives and application of the aminomethylpiperidine derivatives in preparation of drugs used for treating opioid receptor mediated diseases. The aminomethylpiperidine derivatives provided by the invention show affinity activity and agonistic or antagonistic functional activity to mu and delta opioid receptors in an in-vitro experiment, and show analgesic activity with moderate intensity in an animal in-vivo experiment. The aminomethylpiperidine derivatives provided by the invention can be used for preparing the drugs used for treating the opioid receptor mediated diseases, wherein the diseases comprise but are not limited to pains, gastrointestinal diseases, depressive disorders, pruritus, addiction, etc.; and the aminomethylpiperidine derivatives have significant potential clinical application values in treatment of pains.

The invention relates to an intracellular triggering reduction sensitive drug linked gene targeted co-carrier which is a gene and drug double-loaded system and comprises disulfide bond cross-linked polyethylene imine, a poly-lactide glycolide copolymer and a surface modified targeted micromolecule. According to the invention, the surface modified active targeted group of a carrier can target drugs to a tumor part and enrich the drugs; a disulfide bond cross-linked in a polymer can be broken in a cell under the condition of high reduction, and the structure of the carrier is disassembled so that the drugs are released. The intracellular triggering reduction sensitive drug linked gene targeted co-carrier disclosed by the invention can effectively load the gene and the hydrophobic micromolecular drug, ensure the stability of the gene and is degraded and releases the gene and the micromolecular drug under the condition of reduction. An in-vivo experiment shows that the intracellular triggering reduction sensitive drug linked gene targeted co-carrier disclosed by the invention has outstanding targeting on tumors.

The invention relates to the technical field of medicines, and provides application of metrn1 protein in preparation of a lipid-lowering drug or a health-care food. An in vivo experiment shows that the blood lipid level of metrn1 fat cell specificity overexpression mice is obviously lower than that of normal mice when the normal mice and the metrn1 fat cell specificity overexpression mice are supplied with triglyceride lavage; the result shows that the metrn1 protein has an effect of reducing blood lipid. The metrn1 protein is intrinsic protein of a human body. Therefore, the safety of the metrn1 protein as a potential drug is high.

The invention relates to a graphene catheter composition, a catheter preparation method and an application. The graphene catheter composition comprises the following components by the mass percentages: 90-99.5% of a biodegradable material, and 0.5-10% of graphene. The graphene catheter comprises a catheter and a biological adhesion substance layer, and the biological adhesion substance layer is arranged on the inner wall of the catheter; the catheter is prepared by the graphene catheter composition. The preparation method comprises that the graphene catheter composition is printed in 3D or electrospun to produce a catheter; the interior of the catheter is sprayed with a biological adhesion substance by 3D printing or electrospinning, and the catheter is crosslinked and solidified, so thatthe graphene catheter can be obtained. The catheter can promote regeneration, proliferation and differentiation of nerves, blood vessels and the like. In-vivo experiments show that the repair of animal peripheral nerves such as sciatic nerves is superior to that of autologous nerve transplantation, and practical and clinical value is achieved.

The invention provides a tonka bean ethers compound extracted from Compositae plants, the pharmaceutical composition containing the composition, and the use in treating antirheumatic or rheumatoid arthritis, and osteoarthritis. Extracorporal and animal in vivo experiment shows that, the compound can effectively treat and improve the symptoms for these diseases.

The invention relates to the technical field of immunotherapy of infectious diseases, in particular to recombinant gene construction of chimeric antigen receptor (CAR) for treating HIV (human immunodeficiency virus) infection and an application of the CAR. A single-chain antibody (ScFv) can identify gp120 of surfaces of HIV infected cells through series connection of antibody light chain and heavy chain variable zones of the gp120 of the surfaces of the HIV infected cells; the ScFv is prepared into the CAR, CAR coding genes are shifted to plasimid vectors, and lentiviral vectors shifted with the CAR coding genes are transduced to CD8+T lymphocytes. The CD8+T lymphocytes are discovered to be remarkable in restraining and killing activities of the HIV infected cells in both in-vitro and in-vivo experiments and can serve as active ingredients to prepare anti-HIV infection drugs, and good application prospect is achieved.

The invention relates to the separation and extraction methods of a sweet tea polyphenols. The invention uses integration of ultrafiltration with resin adsorption separation technique. Only ethanol is used as organic solvent during producing process and the separation technique of sweet tea polyphenols is optimized; the simple operation helps realize industrialized production; besides, the production process accords with environment protection requirement and the products accord with food and drug raw material requirements. The invention uses Guangxi sweet tea as raw materials to produce sweet tea polyphenols containing over 50% and 90%. Hyaluronidase inhibition in vitro experiment, in vivo experiments of mice passive dermato-allergic reaction and the delayed cutaneous hypersensitivity caused by dinitro-chlorobenzene confirm the invention has significant anti-anaphylaxis activity.

The invention relates to a drug release measuring device and a drug release measuring method which are provided for an endovescular stent. The invention solves the problem that the existing measuring device cannot simulate the condition within a human body or measure the deposition and distribution of the drug on vascular tissues. The method mainly comprises: a buffer solution is prepared; an animal vessel is separated and fixed, the stent is implanted and expanded, and a flow environment within the body is simulated; and samples are collected and tested. The measuring device comprises a reservoir, a silicone tube, a glass tube, a vessel implantation groove, a diaphragm capsule dilatometer, a flow valve, a high pressure gas cylinder and a peristaltic pump, wherein, the reservoir is connected with the vessel container by the glass tube; the vessel implantation groove is connected with the reservoir by the glass tube which contains the diaphragm capsule dilatometer and the flow valve; the reservoirs are connected together by the silicone tube which is provided with the peristaltic pump; the high pressure gas cylinder is connected with the reservoir by the silicone tube. The invention can not only simulate the flow condition within body accurately which can provide better support for the vivo experiment, but also measure the deposition and distribution of the drug on the vasculartissues.

The invention discloses a chromone-containing benzoyl hydrazone compound capable of suppressing growth of cyanobacteria in a general formula I, synthesis of the compound and an in-vivo experiment on the benzoyl hydrazone for suppressing the growth of the cyanobacteria. In the formula, an R<1> represents hydrogen, halogen, C1-C4 alkyl groups or hydroxyl groups, an R<2>, an R<3> and an R<4> respectively represent hydrogen, halogen, hydroxyl groups or trifluoromethyl, and substituent groups represented by the R<2>, the R<3> and the R<4> can be identical or different. In the in-vivo experiment on the compound to microcystis aeruginosa FACHB912 which is the main type of cyanobacteria, a half maximal effective concentration value EC<50> of the compound ranges from 0.17muM to 33.37muM, and thus the compound has a remarkable effect for suppressing the growth of the cyanobacteria and can be used as an effective ingredient of an algicide.

The invention provides small RNA (shR337) capable of differentiating hematopoietic stem cells (MSC) from human nonhematopoietic stem cells (HSC) such as mesenchymal stem cells (MSC). The discovery of the small RNA also provides an action target capable of differentiating the hematopoietic stem cells from the human nonhematopoietic stem cells such as the bone marrow mesenchymal stem cells. The small RNA can restrict the protein translation of EIDI genes after being transfected to human bone marrow mesenchymal stem cells to transform the human bone marrow mesenchymal stem cells into hematopoietic stem cells with CD45<+>surface antigen positive, and the hematopoietic stem cells with CD45<+>surface antigen positive can be further differentiated into myeloid cells and lymphoid cells. Mice in vivo experiments show that the differentiation of the small RNA to the mesenchymal stem cells is directional and undivided.

The present invention provides a human Tim-3-Ig fusion protein which can block Tim-3 signal pathway, and said Ig fusion protein comprises Tim-3 protein, human Ig fragment, and the linking sequence therebetween. In the present invention, a human Tim-3-Ig gene is obtained by an artificial synthesis process; an expression vector containing the Tim-3-Ig gene is constructed; and the prepared Ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice. The human Tim-3-Ig fusion protein prepared in the present invention can be used to treat immunological diseases caused by high expression of Tim-3.

The invention discloses a traditional Chinese medicine composition for treating gastric cancer. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of pilose asiabell root, 15-35 parts of fresh rhizoma atractylodis macrocephalae, 10-20 parts of zedoary, 10-15 parts of rhizoma pinelliae preparata, 10-30 parts of Chinese actinidia root and 10-30 parts of rhodiola rosea. The traditional Chinese medicine composition exerts advantages of comprehensive therapy of traditional Chinese medicine, and dialectics is combined with differentiation of disease; and according to etiology, pathogenesis and pathology features of gastric cancer, experimental observation on an in-vitro experiment for inhibiting gastric cancer SGC7901 cell proliferation by medicines and an in-vivo experiment for inhibiting transplanted tumor of gastric cancer SGC7901 cells in nude mice by medicines shows that the traditional Chinese medicine composition in the invention can induce the SGC7901 cells to produce autophagy so as to inhibit the proliferation of the gastric cancer SGC7901 cells, thereby opening a road for hope for treating patients with gastric cancer.

The invention belongs to the field of pharmaceutical chemistry and in particular relates to an application of a specific piperidone-containing single-carbonyl curcumin compound in preparation of an anti-inflammatory drug and medicines used for treating related inflammation diseases. The curcumin compound can inhibit expression and release of an inflammation-suppressing factor IL-6, obviously reverse degradation of I kappa B related to regulation of inflammation and inhibit phosphorylation of inflammation signal channels such as ERK and JNK; and in vivo experiments show the curcumin compound can obviously improve survival rate of mice which are about to die owning to induction by virtue of LPS (lean process solution).

The invention discloses application of fermentation supernatant liquid of pseudomonas. A pseudomonas bacterial strain is activated in a plate streaking manner, a single colony on a plate is inoculated into a triangular flask filled with a culture medium 2216E, the culture temperature is 28 DEG C, the revolution of a shaker is 180rpm, the culture time is 48h, centrifugation is carried out for 15min at a speed of 8000rpm to obtain the fermentation supernatant liquid A316 which can be used for prevention and control of meloidogyneincognita, and the fermentation supernatant liquid A316 has an antagonism effect in vitro on hot pepper gray molds caused by botrytiscinerea in a greenhouse in-vivo experiment and a good control effect, promotes the growth of hot pepper and has a good application prospect.

The invention provides an inula wissmannian extract and preparation thereof and application in preparation of an antitumor drug. The extract is gemma alkane type sesquiterpene lactone inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone. The extract has the following chemical structural formula and absolute configuration that: due to the toxicity killing function experiment of inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone on human hepatoma cells HepG2, human prostatic cancer cells PC-3, human gastric carcinoma cells MGC-803, human leukemia cells K562, human nasopharynx cancer cells KB and normal human hepatocytes LO2, the result shows that the gemma alkane type sesquiterpene lactone has strong tumor cell killing function, and proliferation of tumor cells can be inhibited, so that the tumor cells are killed. The animal in-vivo experiment proves that the inula wissmannian plant extract and monomeric compounds have the anti-tumor effect and can serve as active ingredients for preparing the antitumor drug. A novel cancer treatment medicine is provided clinically, and high clinical application values and social benefits are generated.